Vyvgart

Active substance efgartigimod alfa
Holder Argenx
Status closed
Indication add-on to standard therapy treatment for patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and who demonstrate inadequate response to conventional treatments, are not clinically eligible or with contra-indication to treatment with approved and commercially available treatment and are not eligible to participate in a clinical trial
Public documents Approbation
  Approbation amendment
  Information for the patient
  Informed consent
Last update

07/02/2024

Last updated on 13/02/2024